Oncopeptides AB (FRA:OND) OCF Margin %: -179.59% (As of Mar. 2026)

What is Oncopeptides AB OCF Margin %?

Oncopeptides AB FRA:OND -1.30% 30 OCF Margin % is -179.59% as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 30/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Oncopeptides AB ranks worse than 63.09% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Oncopeptides AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €-4.23 Mil. Oncopeptides AB's Revenue for the three months ended in Mar. 2026 was €2.36 Mil. Therefore, Oncopeptides AB's OCF Margin % for the quarter that ended in Mar. 2026 was -179.59%.

As of today, Oncopeptides AB's current OCF Yield % is -31.27%.

The historical rank and industry rank for Oncopeptides AB's OCF Margin % or its related term are showing as below:

FRA:OND' s OCF Margin % Range Over the Past 10 Years
Min: -5033.02 Med: -823.34 Max: -313.4
Current: -232.35

During the past 12 years, the highest OCF Margin % of Oncopeptides AB was -313.40%. The lowest was -5033.02%. And the median was -823.34%.

FRA:OND's OCF Margin % is ranked worse than
63.09% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs FRA:OND: -232.35

Oncopeptides AB OCF Margin % Related Terms

Oncopeptides AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB OCF Margin % Chart

Oncopeptides AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-1,281.84

-5,032.89

-793.46

-823.45

-313.40

Oncopeptides AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-515.03	-283.64	-166.74	-323.51	-179.59

FRA:OND vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Oncopeptides AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's OCF Margin % falls into.

Save Embed

30GF Score

Oncopeptides AB FRA:OND

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Oncopeptides AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Oncopeptides AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-20.481	/	6.535
	=	-313.40 %

Oncopeptides AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-4.233	/	2.357
	=	-179.59 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -179.59% mean?

Oncopeptides AB (FRA:OND) has a OCF Margin % of -179.59% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #605 out of 959 companies in the Biotechnology industry, placing it in the top 63.1%.

Is Oncopeptides AB's OCF Margin % too high?

Oncopeptides AB's current OCF Margin % is -179.59%. Based on the distribution chart, Oncopeptides AB ranks #605 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Oncopeptides AB's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #605 out of 959 companies for OCF Margin %. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current OCF Margin % is -179.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Oncopeptides AB stock overvalued right now?

Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.14 — trading 61.6% below its estimated fair value. The current OCF Margin % is -179.59%. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current OCF Margin % is -179.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.14 is trading 61.6% below its estimated GF Value™ of €0.37. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

OCF Margin %: -179.59%
GF Value™: €0.37 vs. price of €0.14 (61.6% below fair value)
GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:FLUO OSTO:IBT B OSTO:CANTA XSAT:CESSA OSTO:CLBIO OSTO:IVACC OSTO:ACE OSTO:SYNACT OSTO:SPRINT OSTO:IMMU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ONCO:Sweden ONCOs:UK 0RN4:UK

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37

Website https://www.oncopeptides.com

Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.

30GF Score

Get the complete analysis for FRA:OND

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14

Price

€0.37

GF Value

View FRA:OND Analysis

See OCF Margin % data for all stocks →